Curriculum vitae

Curriculum Vitae

Dr. med. Klaus Rose (MD, MS)

Curriculum Vitae

Dr. med. Klaus Rose (MD, MS)

Current Address

klausrose Consulting
Pediatric Drug Development & More
Aeussere Baselstrasse 308
4125 Riehen
Switzerland
Phone   +41 61 312 05 10
Mobile   +41 79 102 35 63 / +49 176 9966 9809
klaus.rose@klausrose.net

Personal Data
Born 2nd November 1953 in Heidelberg, Germany
Nationality: German
Married, two daughters

Current Position
Founder and Managing Director, klausrose Consulting, Pediatric Drug Development & more, Riehen, Switzerland

 Education and Qualifications

2004                                 Master’s Certificate in Project Management, The George Washington University School of Business, Washington D.C., USA

2000                                 Equivalence Certificate to Swiss Postgraduate Degree (FMH) in Pharmaceutical Medicine

1999                                 Diploma European Course Pharmaceutical Medicine (ECPM)

1992                                 German Postgraduate Degree in General Medicine

     1986 – 1991                  Postgraduate clinical training in General Medicine in Germany and England (pediatrics, psychosomatic medicine, internal medicine, surgery, geriatrics)

     1979 – 1986                  Study of Medicine in Berlin, Thesis in Medicine

     1972 – 1978                  Study of Latin Languages & Psychology in Heidelberg and Berlin, MS in Psychology

 

Employment History

March 2011 – today   Managing Director, klausrose Consulting, Riehen, Switzerland

2010 – March 2011      Principal Consultant at Granzer Regulatory Consulting, Munich, Germany

2005 – 2009                  Global Head Pediatrics, F.Hoffmann-La Roche Pharmaceuticals,                                                                 Basel, Switzerland

1997 – 2005                  Novartis Pharmaceuticals, Switzerland

                                          2001 – 2005    Global Head Pediatrics

                                          2000 – 2001    Head, Special Projects, Clin Dev & Medical Affairs

1999 – 2000    Senior International Medical Advisor, Basel (HQ)

                                         1997 – 1999    Medical Advisor in Bern (Swiss affiliate)

 

1996                                 Medical Director Lohman Medical, Neuwied, Germany         

1991 – 1996                  Clinical Research Associate, Byk Gulden Pharmaceuticals, Germany (today: Takeda); in parallel: Medical Director, Byk AG, Switzerland        

1986 – 1991                  Postgraduate clinical training in General Medicine in Germany and England (pediatrics, psychosomatic medicine, internal medicine, surgery, medicine for the elderly)

 

Other Professional Activities:    

Regular speaker on international confererences on pediatric drug development; member of DIA and EAP, facultuy member of several institutions that train in drug development and clinical research (ECPM, FORUM, others)  

 

International Leadership

05/2014 – 2017                           Co-Chairman Organizing Committee, Basel International Conference on Drug Development in Pediatric & Rare Diseases

1/2005 to 12/2014                    Chairman, EFGCP Children’s Medicines Working Party

2006 – 2009                                 Chairman, DIA Pediatric SIAC

8/2008 – 10/2009                      Chairman, IFPMA (www.ifpma.org) Pediatric Task Force

 

Professional Experience

After clinical training started in Byk Gulden, Konstanz, Germany (today: Takeda) as a clinical trial physician. Run two phase 1 trials and several large international pantoprazole phase 3 trials in Europe and Latin America. Worked in parallel at Byk Gulden Switzerland as Medical Director. Trained the sales representatives in gastroeneterology (pantoprazole), pneumology (theophyllin), cardiovascular diseases (omega-3-oil capsules), and other areas.

Worked ½ year in Lohman Medical Devices in Germany, buildung up the fundaments of a medical affairs team.

Worked in Novartis Switzerland as clinical trial physician in the areas of oncology, dermatology, pneumology, gastroenterology and central nervous system.

Was promoted to Novartis International Headquarter as Senior International Medical Advisor. Built up the international Medical Communication function and established the cross-functional Pediatric Advisory Group (PAG) in 2000 to improve the company’s handling US pediatric legislation, specifically 6 months Pediatric Exclusivity (patent prolongation). Advised teams in building pediatric development plans across all development functions (preclinical toxicology & safety; galenic formulations; modelling & simulation (M&S) / Clinical Pharmacology; Clinical Development; Post-Marketing Commitments) and across all indication areas. Networked with the top 20 pharmaceutical companies for cooperation in pediatric drug development, resulting in annual pediatric conferences between academia, regulatory authorities, and industry.

Moved to Roche in 2005, established there a cross-functional pediatric drug development structure. Worked with teams across all development functions and  indication areas. Advised teams on EMA / PDCO (pediatric committee) pediatric investigation plans (PIPs) when the EU pediatric regulation came into force in 2007. Established and co-chaired  the pediatric taskforce of the IFPMA (International Federation of Pharmaceutical Industries).

With the move to Granzer Regulatory Consulting in 2010 responsible for hands-on preparation, writing, submission & negotiation of PIPs with the EMA / PDCO. Sucessfully concluded 8 PIPs from early preparation to final acceptance by EMA. 

With establishing an own company, advised US & EU based companies on strategies in handling FDA & EU regulatory pediatric requirements and continued to prepare, write, submit and negotiate PIPs (EMA) and pediatric plans (FDA). Established in 2015 the Basel annual international conference on drug development in pediatric and rare diseasese. The 3rd one will take place in February 2017

International networking in pediatric drug development: regular presentations on international conferences, publications in international scientific journals, and co-editing books on pediatric drug development.

Leadership Skills

Most responsabilities were performed in a matrix structure coordinating up to 25 people in general issues of pediatric drug development both in Novartis and Roche. Pediatrics was usually 10 – 20% of coordinated persons’ KPI’s which had to be evaluated annually. Maximum number of direct reports was five.

Publications

  • Rose K. The Challenges of Pediatric Drug Development. Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.007
  • Rose K, Neubauer D, Grant-Kels JM. Questionable Industry-Sponsored Studies in children and adolescents in Slovenia. Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.002
  • Rose K, Walson PD. Are Regulatory Age Limits in Pediatric Melanoma Justified? Curr Ther Res Clin Exp. 2019, https://doi.org/10.1016/j.curtheres.2019.01.003
  • Rose K, Grant-Kels JM. Pediatric Melanoma – The Whole (Conflicts Of Interest) Story. Int J Womens Dermatol 2018, https://doi.org/10.1016/j.ijwd.2018.10.020
  • Rose K, Grant-Kels JM. The Meanings of „Pediatric Drug Development“. A Review. Therapeutic Innovation and Regulatory Science 2018, https://journals.sagepub.com/doi/pdf/10.1177/2168479018812060
  • Rose K, Grant-Kels JM. FDA/EMA-triggered paediatric studies: Do they really advance child health? Regulatory Rapporteur (TOPRA) Vol 15, No 9, September 2018
  • Rose K. Kinder brauchen nur sinnvolle Studien (Children need only reasonable clinical studies). pädiatrische praxis 2018;90(4):705-716
  • Rose K, Grant-Kels JM. Questionable International Pediatric Studies in the United States and Russia Triggered by Regulatory Authorities. Asian Journal of Research in Medical and Pharmaceutical Sciences 2018,3(3). http://www.journalrepository.org/media/journals/AJRIMPS_63/2018/Apr/Rose332018AJRIMPS40776.pdf
  • Rose K, Grant-Kels JM. Questionable Industry-Sponsored Pediatric Studies in China Triggered by United States of America (US) and European Union (EU) Regulatory Authorities. SF Pharma J 2018,1:1. https://www.scifedpublishers.com/open-access/questionable-industry-sponsored-pediatric-studies-in-china-triggeredby-united-states-of-america-us-and-european-union-eu-regulatoryauthorities.pdf
  • Rose K, Grant-Kels JM. Pediatric Melanoma and Drug Development. Children (Basel). 2018 Mar 20;5(3). http://www.mdpi.com/2227-9067/5/3/43
  • Rose K, Grant-Kels JM. Questionable International Pediatric Studies With Swiss Participation. Swiss Med Wkly 2018, https://smw.ch/fileadmin/content/blog/PDF/Questionable_pediatric_studies_with_Swiss_participation.pdf
  • Rose K, Grant-Kels JM. Most adolescents’ melanomas are conventional malignant adult-type melanomas. Eur J Cancer. 2018 May;95:117-119.
  • Rose K, Benisheva-Dimitrova T. EU paediatric investigation plans (PIPs) might harm children. Acta Med Bulg 2018, 45(1): 5-10. https://www.degruyter.com/downloadpdf/j/amb.2018.45.issue-1/amb-2018-0001/amb-2018-0001.pdf
  • Tsilochristou O et al.: Current state and future of Paediatric Allergology in Europe: A road map. Pediatr Allergy Immunol. 2017 Nov 23
  • Rose K, Walson PD. Do Pediatric Investigation Plans (PIPs) Advance Pediatric Healthcare? Pediatr Drugs 2017, 19(6), 515-522
  • Rose K. Moderne Medikamente und ihre Entwicklung für Kinder – Leicht gesagt, schwierig umzusetzen: Die von der Europäischen Zulassungsbehörde geforderten Kinderentwicklungspläne für Allergenprodukte für die Spezifische Immuntherapie. Pädiatrische Allergologie 1/2017, 16-30
  • Rose K, Happle R: The Impact of Regulation on Pediatric Psoriasis Drug Approvals: The Challenge of the European Union (EU) Pediatric Investigation Plans. Pediatr Dermatol. 2017 May;34(3):e154-e159.
  • Rose K & Walson PD: Do the European Medicines Agency (EMA) Decisions Hurt Pediatric Melanoma Patients? Clinical Therapeutics 2017, 39(2), 253-265 https://www.clinicaltherapeutics.com/article/S0149-2918(17)30047-4/pdf
  • Rose K: New Drugs For Rare Diseases in Children. Clinical Therapeutics 2017, 39(2), 246-252 https://www.clinicaltherapeutics.com/article/S0149-2918(17)30050-4/pdf
  • Rose K: Gut gemeinte Regeln führen zu sinnlosen Studien – Abbruch zweier fragwürdiger pädiatrischer Melanomstudien. Ars Medici 22, 2016, 1014 rosenfluh.ch/media/arsmedici/2016/22/Gut-gemeinte-Regeln-fuehren-zu-sinnlosen-Studien.pdf
  • Rose K: Fragwürdige Studien gefährden Patienten – Neue EU-Zulassungsvorschriften führen zu Diskussionen in der Schweiz. Pädiatrie 6/2016, 29-31 rosenfluh.ch/media/paediatrie/2016/06/Fragwuerdige-Studien-gefaehrden-Patienten.pdf  
  • Rose K: Medikamente und ihre Entwicklung für Kinder. Schweizerische Ärztezeitung 2016;97(46):1620–1622 www.saez.ch/docs/saez/2016/46/de/SAEZ-04880.pdf
  • Rose K & Mueller T: Children with Multiple Sclerosis Should Not Become Therapeutic Hostages. Ther Adv Neurol Disord 2016, Vol. 9(5) 389–395 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994785/pdf/10.1177_1756285616656592.pdf
  • Rose K: Pediatric Strategies. In: Siegenthaler M & Sietsema W (Editors): Global Pharmaceutical and Biologics Regulatory Strategy. 2016, Regulatory Affairs Professionals Society, Rockville, MD, USA, pp. 83-95
  • Rose K & Kopp MV: Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health. Pediatr Allergy Immunol. 2015 Dec;26(8):695-701
  • Rose K, Walson PD: The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood Risk Manag Healthc Policy.2015 Nov 5;8:185-205. https://www.dovepress.com/the-contributions-of-the-european-medicines-agency-and-its-pediatric-c-peer-reviewed-fulltext-article-RMHP
  • Rose K & Kummer H: A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials. Children 2015, 2, 198-210 http://www.mdpi.com/2227-9067/2/2/198
  • Rose K & Spigarelli MG: Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency. Children 2015, 2, 108-130; https://www.mdpi.com/2227-9067/2/1/108
  • Rose K & Senn S: Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee—adolescents’ melanoma as a paradigm. Pharmaceutical Statistics 2014; 13(4): 211-213
  • Rose K: The Vision of Better Medicines for Children and the Role of Regulatory Authorities. Pharmaceutical Regulatory Affairs 2014; 3:2 http://omicsgroup.org/journals/the-vision-of-better-medicines-for-children-and-the-role-of-regulatory-authorities-2167-7689.1000e127.pdf
  • Rose K: European Union Pediatric Legislation Jeopardizes Worldwide, Timely Future Advances in the Care of Children With Cancer. Clinical Therapeutics 2014, 36 (2), 163-177 http://www.clinicaltherapeutics.com/article/S0149-2918(14)00018-6/pdf
  • Bar-Shalom D & Rose K: Pediatric Formulations – A Roadmap (Textbook). AAPS & Springer, 2014. ISBN: 978-1-4899-8010-6
  • Bar-Shalom D & Rose K: Pediatric Formulations – A Roadmap (Textbook), introduction: free download @: http://www.springer.com/us/book/9781489980106#reviews
  • Rose K: Clinical Testing in Children. In: Bar-Shalom D & Rose K: Pediatric Formulations – A Roadmap, AAPS & Springer, 2014: chapter 25, pp. 365 – 376
  • Rose K: Pediatric Pharmaceutical Legislation in the USA and EU and Their Impact on Adult and Pediatric Drug Development. In: Bar-Shalom D & Rose K: Pediatric Formulations – A Roadmap, AAPS & Springer, 2014: chapter 28, pp. 405-420
  • Rose K: A Paediatric Investigation Plan Case Study. Pharm Med 2012; 26 (5): 287-295
  • Rose K: Pediatric Drug Development. A Closing Thought. Applied Clinical Trials 2012; 21 (11), 50
  • Rose K: Impact of EU & US Pediatric Legislation on Industry, Authorities & Academia. American Pharmaceutical Review, online, December 2011
  • Rose K & della Pasqua O: Development of Paediatric Medicines: Concepts and Principles. in Seyberth, HW. Rane A, Schwab M (Eds.): Pediatric Clinical Pharmacology (Handbook of Experimental Pharmacology Vol. 205), Springer, September 2011
  • Rose, K. (2011): The value of juvenile animal studies: a pediatric clinical perspective. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2011; 92 (4), 252-253
  • Rose K & van den Anker JN (Editors): Guide to Paediatric Drug Development and Clinical Research. Karger, May 2010, ISBN-10: 3805593627, ISBN-13: 978-3805593625
  • Staatz I & Rose K: Paediatric Legislation – A Potential Roadblock to New Drugs in Europe. Business Development & Licensing Journal (www.plg-uk.com), issue 11, January 2010
  • Rose K: Grosse Anstrengungen für die Kleinen. VSAO Journal 6 / 2009, 24-25 http://www2.vsao.ch/fileupload/2009112693351_pdf.pdf
  • Rose K: Challenges in Pediatric Drug Development. A Pharmaceutical Industry Perspective. Pediatr Drugs 2009; 11 (1): 57-59
  • Rose K: Ethical Principles of Pediatric Research and Drug Development. Chapter 11 in: Pediatric Drug Development – Concepts and Applications. Mulberg AE, Silber SA & van den Anker, JN (Editors), Wiley-Blackwell, 2009
  • Rose K: European Perspectives. Chapter 13 in: Pediatric Drug Development – Concepts and Applications. Mulberg AE, Silber SA & van den Anker, JN (Editors), Wiley-Blackwell, 2009
  • Rose K: Ethical, Regulatory and Scientific Challenges in Paediatric Drug Development. Pharm Med 2008; 22 (4): 221-234
  • Golombek SG, van den Anker JN & Rose K: Clinical Trials in Children. Ethical and Practical Issues. Int J Pharm Med 2007; 21 (2): 121-129
  • Rose K & van den Anker JN (Editors): Guide to Paediatric Clinical Research. Karger 2007; ISBN-10: 3–8055–8201–3 / ISBN-13: 978–3–8055–8201- 8                                                          
  • Rose K: Integration of pediatric aspects into the general drug development process Ernst Schering Res Found Workshop. 2007;(59):123-134
  • Rose K: Which industry-sponsored pediatric research programs can be expected to be triggered by the EU pediatric regulation? Standardy Medyczne 2005; 5: 1897 – 1900
  • Rose K: European Draft Pediatric Regulation and Challenges in Pediatric Drug Development: Jap J Clin Pharmacol & Ther 2005;18 (1) 9-14
  • Rose K: Better medicines for children – where are we now, and where do we want to be? Br J Clin Pharmacol. 2005; 59(6): 657-659.

Languages                                   

Fluent in German, English, Spanish, Italian, French. Basics of Portuguese, Hungarian, modern Greek.

Private interests                       

Family, Classical Guitar, Latin Culture, Hungarian Language, Cooking, Gardening, Wine

Riehen, February 2019